NantWorks Pays $50M For Majority Stake In Precision Biologics
socalTECH
OCTOBER 19, 2015
Los Angeles-based NantWorks said this morning that it has acquired a majority stake in Precision Biologics with a $50M investment in the company. Precision Biologics is a biopharmaceutical company which is developing tumor-specific monoclonal antibodies (mAbs) and companion diagnostics to treat solid-tumor cancers. NantWorks said the acquisition will help bolster its cancer treatment efforts.
Let's personalize your content